Acurx Pharmaceuticals Stock Is Plummeting After Biotech Publishes Phase 2 Results - Acurx Pharmaceuticals (NASDAQ:ACXP)
Acurx Pharmaceuticals Inc (NASDAQ: ACXP) shares are trading lower after the company
Source: benzinga.com
Page 3 - Modified Intent News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Modified Intent. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Modified Intent Today - Breaking & Trending Today
Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection
In a total of 26 ibezapolstat-treated patients in Phases 2a and 2b, the Clinical Cure rate is 96% Meets protocol primary objective of assessing the primary...
Source: prnewswire.com
Pliant Therapeutics Announces Positive Data from the
Bexotegrast demonstrated statistically significant increase in FVC at 4, 8 and 12 weeks of treatment, outperforming lower dose groups No...
Source: globenewswire.com